Cargando…
A tailored phase I-specific patient-reported outcome (PRO) survey to capture the patient experience of symptomatic adverse events
BACKGROUND: Patient perspectives are fundamental to defining tolerability of investigational anti-neoplastic therapies in clinical trials. Phase I trials present a unique challenge in designing tools for efficiently collecting patient-reported outcomes (PROs) given the difficulty of anticipating adv...
Autores principales: | Janse van Rensburg, Helena J., Liu, Zhihui, Watson, Geoffrey A., Veitch, Zachary W., Shepshelovich, Daniel, Spreafico, Anna, Abdul Razak, Albiruni R., Bedard, Philippe L., Siu, Lillian L., Minasian, Lori, Hansen, Aaron R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10421959/ https://www.ncbi.nlm.nih.gov/pubmed/37419999 http://dx.doi.org/10.1038/s41416-023-02307-w |
Ejemplares similares
-
Longitudinal efficacy and toxicity of SARS-CoV-2 vaccination in cancer patients treated with immunotherapy
por: Spiliopoulou, Pavlina, et al.
Publicado: (2023) -
Predicting response and toxicity to PD-1 inhibition using serum autoantibodies identified from immuno-mass spectrometry
por: Music, Milena, et al.
Publicado: (2020) -
Survival in Early Phase Immuno-Oncology Trials: Development and Validation of a Prognostic Index
por: Day, Daphne, et al.
Publicado: (2019) -
Predicting Toxicity and Response to Pembrolizumab Through Germline Genomic HLA Class 1 Analysis
por: Iafolla, Marco A J, et al.
Publicado: (2020) -
Circulating Biomarkers for Therapeutic Monitoring of Anti-cancer Agents
por: Janse van Rensburg, Helena J, et al.
Publicado: (2022)